Based on our Pharmacor advisory service entitled
Obesity, Decision Resources is offering an exclusive analyst call entitled
Who Will Be the Winners and Losers in the Obesity Wars? Fallout from the FDA Advisory Committee’s Vote on Qnexa. Because this presentation will feature major updates, it is
ONLY available to purchasers of this Pharmacor advisory service.
Recorded live on Tuesday, August 3, 2010
This 15-minute analyst call, presented by Decision Resources Director of Metabolic Disorders Donny Wong, Ph.D., answers the following questions:
- What concerns about Qnexa emerged during the FDA advisory committee meeting and how will these factors impact the approval prospects for Qnexa, Contrave and lorcaserin?
- What are the current opinions of thought leaders regarding the regulatory environment and market potential for Qnexa, Contrave and lorcaserin?
- Through 2019, how will the dynamics of the obesity market change as a result of recent market events?
Contact us to learn how you can purchase this service and access a recorded playback of this event.
Click here to view the invite.